10 Stocks Crash Hard Alongside Wall Street

3. Apogee Therapeutics, Inc. (NASDAQ:APGE)

Apogee Therapeutics fell by 17.32 percent on Monday to end at $39.24 apiece as investors disposed of positions amid the broader market pessimism, shunning positive results from the company’s clinical trial for the treatment of eczema.

On Monday, Apogee Therapeutics, Inc. (NASDAQ:APGE) said the phase 2 clinical trial of the APG777 antibody met all primary and key secondary endpoints and exceeded trial objectives.

At the 16th week of the trial, Apogee Therapeutics, Inc. (NASDAQ:APGE) said that APG777 demonstrated a 66.9-percent improvement in the Eczema Area and Severity Index-75 (EASI-75) score, the highest topline and placebo-adjusted efficacy of any biologic in a global study.

“APG777 has the potential to set a new standard of care by offering improved clinical responses with transformational quarterly or better maintenance dosing, benefitting patients, providers, and payers. Today’s results bring us closer to that vision, and we believe further de-risks APG777’s path to approval,” said Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Henderson.